Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1098264 | 0.86 | KMT2A (0.36) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL1099307 | 0.77 | KMT2A (0.39) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL178300 | 0.77 | KMT2A (0.44) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL9157084 | 0.75 | KMT2A (0.42) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL479863 | 0.75 | ALOX15 (0.57) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL23226887 | 0.75 | ALDH1A1 (0.39) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL898008 | 0.75 | ALDH1A1 (0.43) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL356238 | 0.75 | KMT2A (0.38) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL22025526 | 0.75 | KMT2A (0.42) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL4360988 | 0.73 | KMT2A (0.41) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562955-B1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| EP-1218353-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2007-10-17 | — | — | EP | claimed |
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | claimed |
| EP-1562955-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2005-08-17 | — | — | EP | claimed |
| WO-2004041829-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | claimed |
| US-8153643-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | disclosed |
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090076075-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-7501516-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | disclosed |
| EP-0757051-B1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2003047584-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003047582-A1 | QUINOLINE DERIVATIVES AS ANTITUMOUR AGENTS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003045395-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| WO-2001094341-A9 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003008409-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | disclosed |
| WO-2002092578-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | disclosed |
| EP-0757051-A1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076075-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, NRAS | KMT2A 1423/4885MEN1 514/4885CYP2C19 1077/4885 |
| US-20090233924-A1 | Quinazoline derivatives | AQP1, PGF, F12 | KMT2A 3566/4885MEN1 662/4885CYP2C19 417/4885 |
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | SRC, ABL1, ERBB2 | KMT2A 637/4885MEN1 3039/4885CYP2C19 196/4885 |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, CCNA1 | KMT2A 1159/4885MEN1 616/4885CYP2C19 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.